Home > Insider Trading > Filing (0000950170-25-102537)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1814114	Orchestra Biomed Holdings Inc.	OBIO	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1164426	Joseph Edelman	51 Astor Place, 10Th Floor New York NY 10003	No	No	No	No
1224962	Perceptive Advisors Llc	51 Astor Place, 10Th Floor New York NY 10003	No	No	No	No
1249675	Ltd Fund Master Sciences Life Perceptive	51 Astor Place, 10Th Floor New York NY 10003	No	No	No	No

Transaction Summary

Purchased:	700,000 shares	Avg. Price: $2.75	Total Value: $1,925,000.00
Number of Shares After Transactions:	5,292,556 shares

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2025-08-01	700,000	$2.75	5,292,556	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See Footnote

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Pre-funded Warrants (right to buy)	Acquisiton	2025-08-01	1,500,000	$2.75	1,500,000	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
1,500,000			No	4	P	Indirect

Footnotes

Represents the purchase price for each share of Common Stock purchased by the Reporting Person in the Issuer's registered public offering that closed on August 1, 2025.
The securities are directly held by Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of the Master Fund. Joseph Edelman ("Mr. Edelman") serves as the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of their indirect pecuniary interest therein, and this report shall not be deemed an admission that the Advisor or Mr. Edelman are beneficial owner of such securities for purposes of Section 16 or for any other purposes.
The pre-funded warrants are immediately exercisable and will expire on the date they are exercised in full, subject to the Beneficial Ownership Limitation.
Represents the purchase price for each pre-funded warrant purchased by the Reporting Person in the Issuer's registered public offering that closed on August 1, 2025.